All News

Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.

Amivantamab/chemotherapy has been recommended for approval by the CHMP in advanced non–small cell lung cancer with EGFR exon 20 insertion mutations.

Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.

Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.

Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Findings from the CheckMate-901 trial support the CHMP’s positive opinion of nivolumab plus chemotherapy in metastatic urothelial carcinoma.

Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.

A mobile app may help to expedite treatment and identification for patients with GVHD.

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

One of the most important roles of a nurse coordinator is transmitting patient and caregiver information during the CAR T-cell treatment process.

Researchers from MSKCC have explored the potential of personalized fludarabine dosing, based on population pharmacokinetics, to enhance the outcomes of CD19 CAR T-cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.

Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.

Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.

The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.

Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.

The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.

Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.